Randomized Trialmoderate evidence

Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial.

Nature medicine·November 8, 2026·PMID 43000112

Why it matters

Obesity-related HFpEF is common and difficult to treat; semaglutide's hemodynamic benefits may be mediated by improvements in cardiac structure and function. This mechanistic insight supports the use of GLP-1 receptor agonists in this population and may guide monitoring of cardiac remodeling.

Infographic summary of Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled